$ News

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

HYPE Rises 8% as Hyperliquid Strategies Seeks $1 Billion to Grow Token Treasury

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Sonnet Releases Virtual Investor "What This Means" Segment

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Top Midday Gainers

Traders Digest Tariff Announcements, Driving Premarket Losses for US Equity Futures

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Sonnet Releases Virtual Investor "What This Means" Segment

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Sonnet Announces Release of Corporate Update Video

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer